Biomarin Pharmaceutical Aktie
62,78
EUR
-0,60
EUR
-0,95
%
66,15
USD
+0,13
USD
+0,20
%
Biomarin Pharmaceutical Aktie Analyse
14.12.18 | Biomarin Pharmaceutical Outperform | Wolfe Research | |
01.10.18 | Biomarin Pharmaceutical Overweight | Cantor Fitzgerald | |
07.08.18 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
03.08.18 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
16.05.18 | Biomarin Pharmaceutical Buy | Canaccord Adams | |
15.09.17 | Biomarin Pharmaceutical Sector Perform | RBC Capital Markets | |
14.07.17 | Biomarin Pharmaceutical Outperform | BMO Capital Markets | |
30.03.17 | Biomarin Pharmaceutical Neutral | UBS AG | |
Werbung
|
|||
02.03.17 | Biomarin Pharmaceutical Neutral | Instinet | |
08.12.16 | Biomarin Pharmaceutical Buy | Gabelli & Co | |
03.11.16 | Biomarin Pharmaceutical Buy | Deutsche Bank AG | |
08.04.16 | Biomarin Pharmaceutical Outperform | BMO Capital Markets | |
08.03.16 | Biomarin Pharmaceutical Outperform | Robert W. Baird & Co. Incorporated | |
03.03.16 | Biomarin Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
29.02.16 | Biomarin Pharmaceutical Neutral | Wedbush Morgan Securities Inc. | |
26.02.16 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
25.11.15 | Biomarin Pharmaceutical Perform | Oppenheimer & Co. Inc. | |
08.07.15 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
19.06.15 | Biomarin Pharmaceutical Neutral | Robert W. Baird & Co. Incorporated | |
18.06.15 | Biomarin Pharmaceutical Buy | Deutsche Bank AG | |
18.06.15 | Biomarin Pharmaceutical Buy | Canaccord Adams | |
18.06.15 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
05.06.15 | Biomarin Pharmaceutical overweight | Barclays Capital | |
27.03.15 | Biomarin Pharmaceutical Buy | UBS AG | |
27.03.15 | Biomarin Pharmaceutical Buy | Deutsche Bank AG | |
19.12.14 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
11.12.14 | Biomarin Pharmaceutical Buy | UBS AG | |
25.11.14 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
24.10.14 | Biomarin Pharmaceutical Outperform | RBC Capital Markets | |
06.11.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
03.09.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
28.08.12 | Biomarin Pharmaceutical hold | Deutsche Bank Securities | |
23.07.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
22.06.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
01.06.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
17.02.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
13.02.12 | Biomarin Pharmaceutical outperform | RBC Capital Markets | |
12.12.11 | Biomarin Pharmaceutical buy | Citigroup Corp. | |
08.12.11 | Biomarin Pharmaceutical buy | Citigroup Corp. | |
07.12.11 | Biomarin Pharmaceutical buy | Jefferies & Company Inc. | |
29.09.11 | Biomarin Pharmaceutical buy | Deutsche Bank Securities | |
25.10.10 | Biomarin Pharmaceutical neutral | Wedbush Morgan Securities Inc. | |
17.08.10 | Biomarin Pharmaceutical neutral | Wedbush Morgan Securities Inc. | |
16.04.10 | Biomarin Pharmaceutical kaufen | Der Aktionär | |
29.10.09 | Biomarin Pharmaceutical outperform | Credit Suisse Group | |
22.10.09 | Biomarin Pharmaceutical buy | Citigroup Corp. | |
19.10.09 | Biomarin Pharmaceutical hold | ROTH Capital Partners, LLC | |
08.10.09 | Biomarin Pharmaceutical buy | Jefferies & Company Inc. | |
03.08.09 | Biomarin Pharmaceutical neutral | Wedbush Morgan Securities Inc. | |
31.07.09 | Biomarin Pharmaceutical buy | Jefferies & Company Inc. |